2 Information about solriamfetol

Marketing authorisation indication

2.1 Solriamfetol (Sunosi, Jazz Pharmaceuticals) has a marketing authorisation 'to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy)'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.


2.3 The list price for solriamfetol is £177.52 for a 75 mg 28‑day pack and £248.64 for a 150 mg 28‑day pack (BNF online accessed October 2021). Costs may vary in different settings because of negotiated procurement discounts.

  • National Institute for Health and Care Excellence (NICE)